EnteroBiotix
EnteroBiotix is a clinical-stage microbiome therapeutics company developing an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome.
- Company
- Bellshill, Lanarkshire, GBUnited Kingdom
EnteroBiotix is a clinical-stage microbiome therapeutics company developing an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome.
enterobiotix.comCrawled Oct 24, 2026
Delivered positive Phase 1b clinical data in liver cirrhosis, with results presented at EASL 2025
Today EnteroBiotix announced that the investigator-initiated Phase 2a MAST trial (Intestinal Microbiota Transplant prior to Allogeneic Stem Cell Transplantation) has completed its enrolment of 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for defined haematological malignancies.
The funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBS. Dosing of first patient of the Phase 2b ‘RISE’ trial anticipated in Q2 2026, and topline efficacy data anticipated in H2 2027.
EnteroBiotix today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in irritable bowel syndrome (IBS) have been selected as a Poster of Distinction at Digestive Disease Week (DDW) 2026. The designation is awarded to abstracts rated in the top 10% of all submissions accepted for poster presentation. DDW 2026 takes place at McCormick Place Convention Center in Chicago, Illinois, from 2–5 May 2026.
Angela is the EHS Manager, Health & Safety Department, based in Glasgow.
Become a part of our pioneering team. EnteroBiotix is growing rapidly. If you are passionate about improving the health of others and working on big problems, we are always looking for talented, ambitious, collaborative and adaptable people.
Claire is Associate Director Donor Operations & Biosafety.
Director of Portfolio & Site Operations, based in Glasgow
Led by an entrepreneurial and experienced management team, supported by a distinguished Board, we're on a mission to transform the lives of patients through best-in-class gut therapeutics
Say hello to the future of modern medicine. Find out more about our microbiome modulating therapeutics. Find our facilities in Aberdeen or Glasgow
This Cookie Policy was last updated on 18th Aug 2022
Welcome to EnteroBiotix’ privacy policy. EnteroBiotix is committed to protecting your privacy and your personal data. This policy explains what personal data we collect from (i) individuals and prospective patients/participants visiting enterobiotix.com (‘EnteroBiotix Website’), (ii) individuals and donors visiting number2.org (‘Number 2 Website’); and (ii) individuals visiting insidematters.health (‘Inside Matters Website’) (collectively the ‘EnteroBiotix Sites’), and how we use it.
EnteroBiotix Limited has announced that the first patient has been dosed in its Phase 2b RISE clinical trial evaluating EBX-102-02 for moderate-to-severe irritable bowel syndrome with constipation (IBS-C).
Jul 2026ClivalNews article
Glasgow-based biotech scaleup EnteroBiotix has secured a major £19 million investment to support one of the world’s largest clinical trials of microbiome-based treatments for irritable bowel syndrome (IBS).
May 2026Glasgow City of Science and InnovationNews article
Glasgow-based life sciences company EnteroBiotix has secured £19 million in funding to support the advancement of its microbiome-based therapies, including a large-scale clinical trial targeting irritable bowel syndrome (IBS). The round was led by Thairm Bio and the Scottish National Investment Bank, with participation from existing investors. The company has raised more than £65 million to date.
May 2026Tech.euNews article
Clinically meaningful improvements in global IBS symptom severity were observed as early as week 1 and sustained through week 7.
Jan 2026HCPLiveNews article